Sociedade Britânica de Farmacologia realizará congresso online
20 de julho de 2020A CAPES emite carta em resposta ao Manifesto das Áreas de Avaliação da Capes
21 de julho de 2020Sociedade Britânica de Farmacologia realizará congresso online
20 de julho de 2020A CAPES emite carta em resposta ao Manifesto das Áreas de Avaliação da Capes
21 de julho de 2020New edition of Pharmacology International. This issue is all about the Covid-19 pandemic that has been keeping the entire world, and of course science, in suspense for months.
The pandemic poses a major challenge for the societies and science worldwide. The great uncertainty, especially at the beginning of the pandemic, in which the health care system of some countries was at the edge of its capacity, led to the great need – also among the public – for fast treatment approaches. As a result, the standards of clinical trials were not always met, and results that had not yet been secured prematurely became public, so that the hopes of some preparations were dashed at an early stage. Hydroxychloroquine is an example of this, which has not only caused no benefit so far, but turned out to be harmful. Studies on hydroxychloroquine have consequently been halted by WHO and FDA.
It is the responsibility of experimental and clinical pharmacology to urge compliance with clinical and clinical trial standards if evidence of successful treatment of Covid-19 disease and SARS-CoV-2 infection should be reached. Several of IUPHAR’s member societies have published excellent statements in this direction. We as the umbrella organization of the global pharmacological societies offer a forum for our members on our homepage iuphar.org where you can find links to major contributions. Some are summarized here in Pharmacology International.
Beyond Covid-19, I would like to draw your attention to the further activities of IUPHAR. The governance review report by Wellspring Consultants has been finalized. I would like to thank already at this stage all officers, members of the executive committee and chairs of the subcommittees as well as leaders of our member societies for their constructive comments. IUPHAR has established working groups to set-up the new governance structure along the recommendations made in the review report under the professional guidance of Wellspring Consulting. Our stakeholders will be involved.
More activities of and around IUPHAR can be found in this new edition of Pharmacology International.
Best wishes and stay healthy.
Yours,
Ingolf Cascorbi
IUPHAR President
